{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035061","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.584862+00:00","generated_at":"2026-06-17T22:14:38.216912+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M","bullets":["Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.","Q4 2022 gross margin 70% vs 68% a year ago; cash $42.0M at Dec 31.","OviTex revenue +26% YoY; OviTex PRS +92% YoY; new NIVIS and OviTex LPR launches.","FY2023 revenue guidance $60-65M (45-57% growth)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035061","json":"https://secwatch.observer/filing/0001104659-23-035061.json","markdown":"https://secwatch.observer/filing/0001104659-23-035061.md","text":"https://secwatch.observer/filing/0001104659-23-035061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/tm239776d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:14:38.216912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bbe6509728b70141075d4d8880d2166522eb411","claim":"TELA Bio, Inc. reported Full year 2023 results: revenue $60 million to $65 million. Guidance initiated.","evidence_excerpt":"Full year 2023 revenue is projected to range from $60 million to $65 million, reflecting growth of 45% to 57% over full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2023"},{"label":"Revenue","value":"$60 million to $65 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e719d7031b6486167d4b1b9f58cc6b7cacf926cf","claim":"TELA Bio, Inc. reported the fourth quarter of 2022 results: revenue $11.6 million, net income $10.0 million.","evidence_excerpt":"Revenue was $11.6 million in the fourth quarter of 2022, an increase of 39% compared to the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$11.6 million"},{"label":"Net income","value":"$10.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eee899a2d9e8b32538728efb73e59de01a274104","claim":"TELA Bio, Inc. reported the full year ended December 31, 2022 results: revenue $41.4 million, net income $44.3 million.","evidence_excerpt":"Revenue was $41.4 million for the full year 2022, an increase of 41% compared to the full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923035061/0001104659-23-035061-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$41.4 million"},{"label":"Net income","value":"$44.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}